Large cell lung carcinoma with solitary jejunal metastasis: no evidence of disease 4 years after treatment
This lung cancer diagnosis at a glance
- Stage at diagnosis
- Stage IV
- Subtype
- Non-Small Cell Lung Cancer
- Biomarkers
- Primary lung tumor and jejunal metastasis shared a KRAS codon 61 mutation; staining supported lung origin.
- Sex
- Female
- Spread to
- jejunum
- Treatment
- surgery, radiation and chemotherapy
- Outcome
- Cancer-Free / NED
Treatment course, step by step
- January 2004 lung bilobectomy for right upper-lobe undifferentiated large cell carcinoma, T2N0M0, no adjuvant therapy
- 11 months later proximal jejunal mass confirmed as solitary lung-cancer metastasis by IHC and identical KRAS codon 61 mutation
- intestinal obstruction treated with side-to-side duodenojejunostomy because tumor resection was not possible
- palliative radiotherapy 15 Gy in 5 fractions to jejunal metastasis stopped bleeding; CT 2 months later showed complete absence of residual tumor
- cisplatin 80 mg/m2 + vinorelbine 30 mg/m2 every 3 weeks for 3 cycles, then stopped because of hearing loss
- no evidence of disease 4 years after jejunal metastasis diagnosis.
What happened, in summary
This 60-year-old woman had a history of superficially invasive urothelial carcinoma of the bladder before she was treated for a right upper-lobe lung cancer in January 2004. CT and FDG-PET at the time showed no lymph node involvement or distant metastases. She underwent lung bilobectomy. Pathology showed an undifferentiated large cell carcinoma measuring 3.3 cm in the lung parenchyma, without pleural invasion or regional lymph node metastasis, staged T2N0M0. No adjuvant treatment was recommended. Eleven months later, she returned with abdominal pain, weight loss, fatigue, and a palpable left abdominal mass. CT and double-balloon enteroscopy showed a mass in the proximal jejunum. Biopsy showed large undifferentiated cells, and immunohistochemistry was positive for TTF-1, CK8/18, CK7, and vimentin, matching the previous lung tumor profile. Mutation testing found the same tumor-specific KRAS codon 61 mutation in the original lung tumor and the jejunal lesion; the prior bladder carcinoma did not have this mutation. The jejunal mass was therefore confirmed as a metastasis from the lung cancer. Two days after diagnosis, intestinal obstruction occurred. At laparotomy, the tumor could not be removed because of mesothelial invasion, so surgeons performed a side-to-side duodenojejunostomy. Postoperative gastrointestinal bleeding stopped after palliative radiotherapy, 15 Gy in 5 fractions. Two months later, CT showed no residual jejunal tumor. She then received 3 cycles of cisplatin and vinorelbine, stopped because of hearing loss. As of January 2010, she was doing well with no evidence of disease 4 years after the jejunal metastasis diagnosis, despite the earlier obstruction and bleeding.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Stage 4 Lung Cancer 384 stories
- Chemotherapy for Stage 4 Lung Cancer 217 stories
- KRAS Mutation Lung Cancer 20 stories
- Chemotherapy for Lung Cancer 386 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer